NasdaqGS:SYREBiotechs
Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC Timeline - Has The Bull Case Changed?
Spyre Therapeutics recently reported that it has completed recruitment for the rheumatoid arthritis (RA) sub-study of its SKYWAY Phase 2 basket trial evaluating SPY072, an extended half-life TL1A-targeting antibody, and has accelerated the expected timing of topline proof-of-concept data to the third quarter of 2026 for RA and the fourth quarter of 2026 for psoriatic arthritis and axial spondyloarthritis.
This progress underscores how basket and platform trial designs could speed clinical...